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The marmoset is an important nonhuman primate model for regenerative medicine. For experimental autologous cell therapy
based on induced pluripotent (iPS) cells in the marmoset, cells must be able to undergo robust and reliable directed
differentiation that will not require customization for each specific iPS cell clone. When marmoset iPS cells were aggregated in
a hanging drop format for 3 days, followed by exposure to dual SMAD inhibitors and retinoic acid in monolayer culture for
3 days, we found substantial variability in the response of different iPS cell clones. However, when clones were pretreated
with 0.05–2% dimethyl sulfoxide (DMSO) for 24 hours, all clones showed a very similar maximal response to the directed
differentiation scheme. Peak responses were observed at 0.5% DMSO in two clones and at 1% DMSO in a third clone. When
patterns of gene expression were examined by microarray analysis, hierarchical clustering showed very similar responses in all
3 clones when they were pretreated with optimal DMSO concentrations. The change in phenotype following exposure to DMSO
and the 6 day hanging drop/monolayer treatment was confirmed by immunocytochemistry. Analysis of DNA content in
DMSO-exposed cells indicated that it is unlikely that DMSO acts by causing cells to exit from the cell cycle. This approach should
be generally valuable in the directed neural differentiation of pluripotent cells for experimental cell therapy.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction particularly with respect to the central nervous system (QiuNonhuman primates (NHPs) offer many advantages for
translational regenerative medicine research because of
their relatedness to humans and their similar physiology,⁎ Corresponding author. Fax: +1 210 562 5093.
E-mail address: hornsby@uthscsa.edu (P.J. Hornsby).
http://dx.doi.org/10.1016/j.scr.2015.05.010
1873-5061/Published by Elsevier B.V. This is an open access article unde
(http://creativecommons.org/licenses/by-nc-nd/4.0/).et al., 2013;). For regenerative medicine, long-term studies
of transplanted cell function (N3 years) will be possible in
NHPs, but are impossible in rodents. Within NHPs, the common
marmoset (Callithrix jacchus), as a small, short-lived, and
rapid-breeding NHP species, has some unique advantages for
long-term efficacy and safety studies (Abbott et al., 2003;
Mansfield, 2003). Marmosets can be housed in a defined
environment and have few known comorbidities (Tardif et al.,r the CC BY-NC-ND license
142 Z. Qiu et al.2011). Several human neurological disorders can be modeled
in marmosets (Qiu et al., 2013). The recent publication of the
annotated marmoset genome further enhances the attrac-
tiveness of this NHP model for biomedical research (Worley et
al., 2014).
In order to enable studies on cell therapy in the marmoset,
particularly autologous cell transplant experiments, we derived
induced pluripotent stem cells (iPS cells) from newborn
marmoset skin fibroblasts (Wu et al., 2010, 2012). Subsequently
we documented a rapid iterative method for developing neural
cell differentiation protocols in marmoset iPS cells (Farnsworth
et al., 2013). For autologous cell therapy experiments to be
feasible, it must be possible to apply a differentiation protocol
to iPS cell clones newly generated from donor animals without
the need to customize the protocol for each cell line or for
each donor. In an autologous cell transplant experiment, both
reprogramming of biopsy-derived cells and the differentiation
of the resultant iPS cells to cells ready for transplantation into
the donor animal must be accomplishedwithin a period of a few
weeks.
In the present experiments, we tested the general
applicability of the previously developed neural differenti-
ation protocol in 3 different marmoset iPS cell lines. As
expected, the protocol worked efficiently for the cell line on
which it was originally developed, but it worked much less
well on the other two cell lines. Variability in the responses
































































Figure 1 Cell line-specific variation in response to a neural differe
subjected to a 6-day differentiation protocol involving 3 days of aggre
exposure to dual SMAD inhibitors and retinoic acid in monolayer cultur
gene mRNAs before and after differentiation were assessed by qPCR.
each gene and cell line, the first value is the level in the undifferentiate
protocol. Values ± S.D. (n = 3); statistically significant changes (p b 0been repeatedly noted (Chang et al., 2008; Osafune et al.,
2008; Hu et al., 2010; Bock et al., 2011). A potential solution
to this variability has been proposed, comprising the prior
treatment of the iPS cells with DMSO at a concentration of
aproximately 1–2% (Chetty et al., 2013). In this study, we
show that marmoset iPS cell clones that were incubated with
0.5–1% DMSO showed greatly enhanced responses to the
differentiation protocol. While the changes in gene expression
in response to directed differentiation were quite variable
among iPS cell clones in the absence of DMSO treatment, they
became robust and uniform following exposure to DMSO. Cell
cycle analysis demonstrated that the action of DMSO is likely
to be more complex than only causing an inhibition of cell
replication.Materials and methods
Marmoset iPS cell clones
Three clonal lines of marmoset iPS cells (B8, 88, 15; Wu et
al., 2010) were grown in E8 medium (Chen et al., 2011)
supplemented with 10% fetal bovine serum (GlobalStem,
Gaithersburg, MD). At the beginning of the differentiation
protocols, cells were removed from the dish with Accutase



































ntiation protocol. Three marmoset iPS cell lines (B8, 88, 15) were
gate formation using a hanging-drop format followed by 3 days of
e (see Materials and methods). Levels of various neuroectodermal
mRNA levels are plotted as Ct(gene)-Ct(β-actin) (log2 scale). For
d iPS cells and the second is the value following the differentiation
.05) indicated by asterisks.
143Marmoset iPS cells: Robust neural differentiation following pretreatment with DMSOdifferentiation medium as described below, or were incu-
bated with DMSO prior to the differentiation treatment.
DMSO pretreatment
Following detachment of the cells with Accutase, cells were
plated in differentiation medium containing various concen-
trations (0.05–2%) of DMSO (Sigma Aldrich, St. Louis, MO).
Differentiation medium comprised DMEM/F12 (Sigma) with
20% KSR (Knockout Serum Replacement; Life Technologies,
Grand Island, NY), 0.32 μM dorsomorphin hydrochloride
(Tocris, Bristol, UK), 0.32 μM SB431542 (Selleck, Houston,
TX), 20 ng/ml FGF2 (Novoprotein, Summit, NJ), 25 μg/ml
insulin (Sigma), 1 nM retinoic acid (all-trans retinoic acid,
Sigma), and 10 μM ROCK inhibitor Y-27632 (Chemdea,
Ridgewood, NJ). Cells were plated in this medium on plates
coated with Matrigel (Corning, Tewksbury, MA).
Differentiation protocol
Following 24 hours of incubation in differentiation medium/
DMSO, cells were removed from the dish with Accutase and
resuspended in differentiation medium without DMSO. Cells
were then permitted to form aggregates using 384-well
hanging-drop plates (3D Biomatrix, Ann Arbor, MI). Each wellFigure 2 DMSO pretreatment of marmoset iPS cells and differentia
prior to hanging-drop aggregate formation (4 days) and exposure to dif
images of marmoset iPS cell clones, B8, 88, and 15.of the hanging drop plate received 3000 cells in 30 μl
differentiation medium. Plates were placed in a humidified
incubator at 37.5 °C for 72 h.
Following this incubation period, the resultant aggregates
were collected from the plates. They were then dissociated
into single cells by incubation in 1 ml 0.25% trypsin/EDTA (Life
Technologies) for 10 min at room temperature. Cells were
transferred into DMEM/F12 medium containing 20% KSR to stop
the digestion and mechanically dissociated. 100,000 cells were
plated per 35 mm Matrigel-coated dish. Cells were plated in
DMEM/F12 containing 20% KSR, 2% B27 supplement (Life
Technologies), 15 μg/ml transferrin (human, Sigma), 10 μM
retinoic acid, 1 μM SB431542, 1 μM dorsomorphin, 3.2 μM SAG
(Sonic hedgehog agonist; EMD Chemicals, Billerica, MA) and
10 μM Y-27632. Cells were maintained in the same medium for
72 h with medium changes at 24 h intervals. Following this
period, cells were harvested for preparation of RNA.Quantitative PCR
Total RNA was isolated from cells using RNA Bee
(Tel-Test, Friendswood, TX) according to the manufacturer's
instructions. A total of 2 μg of RNA was reverse-transcribed
by using superscript II (Life Technologies). Quantitative PCR
was conducted using SYBR green detection and an ABItion protocol. Cells were exposed to 0.5%, 1% or 2% DMSO (1 day)
ferentiation factors in monolayer culture (7 days). Representative
Figure 3 DMSO pretreatment improves response of marmoset iPS cells to the differentiation protocol. Neuroectodermal gene mRNAs were measured following hanging-drop
aggregate formation and exposure to differentiation factors as described in Fig. 1, with the addition of 24 hours DMSO pretreatment (details in Materials and methods). Levels of
mRNAs are plotted as Ct(gene)-Ct(β-actin) (log2 scale). For each gene and cell line, values indicated as "0" are from the undifferentiated iPS cells; " + " indicates values following
differentiation, without DMSO; the arrow indicates the values obtained following differentiation with the addition of 24 hours pretreatment with a range of DMSO concentrations
(0.05%, 0.1%, 0.5%, 1% or 2% DMSO). Values ± S.D. (n = 3); statistically significant changes (p b 0.05) versus the undifferentiated cells indicated by asterisks in the upper row;







Figure 4 mRNA microarray analysis of DMSO/differentiation
protocol in 3 marmoset iPS cell lines; heat maps and selected
upregulated and downregulated genes (see Results). Red indicates
mRNAs elevated following DMSO/differentiation and green indi-
cates downregulated mRNAs.
145Marmoset iPS cells: Robust neural differentiation following pretreatment with DMSO7900HT system (Applied Biosystems, Foster City, CA). Levels
of mRNAs are reported as cycles versusβ-actin, usingmarmoset
gene-specific primers. Sequences of marmoset-specific primers
are listed in Supplemental Table 1. Statistical analyses were
performed using Prism software (Graphpad, La Jolla, CA).
Responses to differentiation and DMSO pretreatment were
analyzed by one-way ANOVA followed by Dunnett's test of
multiple comparisons with a control.
Microarrays
For microarray analysis, pelleted cells were stored in RNAlater
(Life Technologies) and then processed to prepare total RNA
using RNA Bee, according to the manufacturer's instructions.
Total RNA was quantified using a Nanodrop spectrophotome-
ter. The quality of the RNA was verified by 260/280 ratio and
by using a BioRad Experion automatedmicrofluidics system for
analysis of RNA. All samples were high-quality RNA prepara-
tions. Microarray analysis (probe labeling, hybridization and
scanning) was performed using the GeneAtlas Personal
Microarray System and marmoset-specific arrays (catalog #
901831;marmoset gene 1.1 ST array strips; 656,668 probes, 21
probes/gene, 33,971 genes).
Data analyses were facilitated using Partek Express
Affymetrix Edition software (Partek Inc., St. Louis, MO) and
GeneSifter web-based package (PerkinElmer, Waltham, MA).
Partek Express uses RMA (Robust Multi-chip Analysis) which
includes background correction, quantile normalization, and
median polish summarization. The arrays were assessed to be
of good quality. For analyses conducted with Partek Express,
one-way ANOVA was used to identify significantly expressed
geneswith amultiple testing correction (Benjamini-Hockberg)
for false discovery rate (FDR was 5%). The data were further
filtered to omit genes not altered in expression by at least
2-fold or 5-fold. A hierarchical cluster analysis was performed
to assess correlations among the samples and genes of interest
using Euclidean distance and average linkage statistical
methods.
Validation of microarray data by quantitative PCR
(qPCR)
The microarray analysis enabled the identification of highly
upregulated and highly downregulated genes. 6 of the most
upregulated and 6 of the most downregulated genes were
selected for further analysis, using cells pretreated with
0.5% or 1% DMSO. qPCR was performed as described above.
Immunocytochemistry
Following the differentiation protocol, cells were detached
with Accutase and were plated onto Matrigel-coated glass
coverslips. Coverslips were fixed in 4% paraformaldehyde for
immunocytochemistry. After washing three times in PBS, the
samples were permeabilized with 0.2% Triton X-100 for
15 min. At room temperature, coverslips were rinsed several
times in PBS and then incubated in 5% goat serum (Sigma) for
1 hour at room temperature. After the goat serum was
aspirated, the samples were incubated with primary antibod-
ies at 4 °C overnight. After rinsing in PBS three times, samples
were incubated with fluorochrome-labeled secondaryantibodies at room temperature for 1 hour, before rinsing in
PBS. Nuclei were stained with 10 μg/ml DAPI (Sigma) for
10 min. Samples were viewed under a Zeiss Axiovert fluores-
cence microscope. Antibodies used are listed in Supplement
Table 2.
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147Marmoset iPS cells: Robust neural differentiation following pretreatment with DMSOCell cycle analysis
For cell cycle analysis cells were fixed in 70% ethanol and were
stained with propidium iodide by incubation in a solution
comprising 0.1% Triton X-100, 20 µg/ml propidium iodide and
0.2 mg/l RNAse A (catalog #4087, Cell Signaling Technology,
Danvers, MA). Cell cycle analysis was performed using a
Becton Dickinson FACSCalibur (UTHSCSA Flow Cytometry
Core).
Results
We investigated how well different marmoset iPS cell clones
responded to a previously developed directed differentia-
tion protocol (Farnsworth et al., 2013). In this protocol, the
cells are formed into aggregates in hanging-drop plates for
3 days and then exposed to differentiation factors (dual
SMAD inhibitors plus retinoic acid) for 3 days in monolayer
culture. Responses were measured as increase in expression
of a set of 7 genes that were previously used to develop the
protocol (Fig. 1).
The clone that was used in an iterative process of
improving differentiation (B8; Farnsworth et al., 2013)
responded as expected, with increases of up to 100-fold in
the tested genes. However, two other clones (88, 15) that
were previously validated as iPS cells via teratoma formation
(Wu et al., 2010), responded much less well (up to about
8-fold, but also failing to respond at all in some cases).
Moreover these clones showed considerable variability in
response in repeated experiments.
For experimental autologous cell therapy to be feasible,
unselected iPS cell clones must respond reliably and robustly
to differentiation protocols. A previously reported set of
experiments using DMSO pretreatment was shown to improve
the differentiation potential of a wide variety of pluripotent
stem cell lines (Chetty et al., 2013).We therefore investigated
whether 24 hours of incubation in 0.05–2% DMSOwould enable
refractory clones to respond to differentiation factors. During
the 24 h incubation in DMSO cells showed some evidence of
toxicity at the higher concentrations but the pretreatment did
not affect the hanging-drop aggregation and there were no
noticeable differences in cell morphology at the end of the
6 day differentiation protocol (Fig. 2).
The DMSO pretreatment had striking effects on the
response of the 3 iPS cell clones to the differentiation protocol
(Fig. 3). All clones showed increased levels of the 7 mRNAs
that were originally used to develop the differentiation
protocol. Clones 88 and 15, that were refractory to the
protocol in the absence of DMSO, responded robustly following
DMSO pretreatment. For example, NCAD mRNA increased by
about 4-fold in clone 88 and showed almost no effect in cloneFigure 5 qPCR validation of microarray analysis. Upregulated and do
(Fig. 4). mRNAs were measured following the 6 day differentiation p
pretreatment (1% DMSO for clone B8, 0.5% DMSO for clones 88 and 15). L
each gene and cell line, values indicated as "0" are from the undiffer
without DMSO; "+/d" indicates the values obtained following differentiat
(n = 3); statistically significant changes (p b 0.05) versus the undiffere
significant changes (p b 0.05) for DMSO treatment versus the differenti
lower row.15; following DMSO, NCAD increase 45-fold in clone 88 and
30-fold in clone 15. The same pattern was seen in all genes.
Clone B8, which responded well in the absence of DMSO, also
showed increases in several mRNAs. For example, SOX10
increased 8-fold in the absence of DMSO and 80-fold following
DMSO pretreatment. The optimal DMSO concentration dif-
fered among clones; 1% treatment resulted in the largest
increases inmRNA levels in clone B8, and 0.5% gave the largest
increases in clones 88 and 15. The highest concentration used,
2%, did not improve responses in clones 88 and 15. We
therefore selected 1% DMSO pretreatment in clone B8 for
further experiments and 0.5% for clones 88 and 15.
These experiments suggested that DMSO pretreatment was
capable of normalizing the responses of refractory clones.
Maximal levels of mRNAs in the 3 clones were similar following
incubation with DMSO, while they were quite different without
DMSO pretreatment. In order to assess whether the similarity of
response following DMSO extended to a larger number of
genes, we performed a microarray analysis on the 3 iPS cell
clones following optimal DMSO pretreatment and differentia-
tion. We found that the robustness of mRNA increases was a
general response extending to several thousand genes (Fig. 4).
Cluster analysis showed that the three differentiated samples
closely resembled each other and were distinct from the three
undifferentiated iPS cell clones.
In order to verify that the effect of DMSO would apply to
genes not previously selected as part of the differentiation
protocol, we selected 6 upregulated and 6 downregulated genes
from the microarray results to assess the effect of DMSO. qPCR
verified that DMSO pretreatment increased the responses of the
6 upregulated genes in the differentiation protocol (Fig. 5).
Some selected genes (LAMA1, CRYAB, ITGA8) showed very little
response in the absence of DMSO, but strong responses following
DMSO pretreatment. For some other mRNAs weak responses
became more robust following DMSO. For the 6 downregulated
genes, the patterns were more complex, but in all cases DMSO
pretreatment caused the mRNA levels following differentiation
to be very simiar, while they were quite dissimilar in the
absence of DMSO.
As a result of these studies we modified our differentiation
protocol by adding a 24 h incubation with 0.5–1% DMSO prior to
3 days of hanging drop aggregate formation and 3 days of
incubation inmonolayer culturewith differentiation factors. To
verify that this protocol was useful, we performed immunocy-
tochemistry on the differentiated cells. Fig. 6 shows that there
was robust expression of NCAD, SOX10, NKX6.1 and NKX2.2 as
well as the general neural marker βIII tubulin, whereas there
was minimal expression of these proteins in the undifferenti-
ated iPS cells. We therefore concluded that adding a DMSO
pretreatment to the differentiation protocol would be of
general value in experiments that require rapid and robust
differentiation.wnregulated mRNAs were selected from the microarray experiment
rotocol described in Fig. 1, with the addition of 24 hours DMSO
evels of mRNAs are plotted as Ct(gene)-Ct(β-actin) (log2 scale). For
entiated iPS cells; " + " indicates values following differentiation,
ion with the addition of 24 hours pretreatment DMSO. Values ± S.D.
ntiated cells indicated by asterisks in the upper row; statistically
ated cells without DMSO pretreatment indicated by asterisks in the
Figure 6 Immunocytochemical confirmation of expression of some DMSO-responsive genes. Marmoset iPS clone B8 cells were
incubated for 24 hours in 1% DMSO and then subjected to the 6 day differentiation protocol described in Fig. 1. Cells were plated on
glass coverslips for immunocytochemistry with antibodies against NCAD, Sox10, Nkx2.2 and Nkx6.1 (green fluorescence; see Materials
and methods). In each case the cells were also stained with an antibody against βIII tubulin (red) and were costained with DAPI (blue).
For each of 4 the genes the upper images are of the cells following differentiation and the lower images are of the undifferentiated
iPS cells.
148 Z. Qiu et al.As noted above, the use of DMSO pretreatment in this
modified protocol was based on prior data that suggested
that this may be of general use in the differentiation of
pluripotent cells (Chetty et al., 2013). In the prior work, it
was suggested that DMSO might act by causing the cells to
exit from the cell cycle. We tested whether marmoset
iPScells are caused to exit from the cell cycle by exposure to
DMSO (Fig. 7). Flow cytometric analysis of propidiumiodide-stained cells showed no effect of DMSO on cell cycle
distribution when used at 0.5%, 1% and 2%.Discussion
In experimental autologous cell therapy in NHPs, rapid and
reliable differentiation is essential for the accomplishment
Figure 7 Effect of DMSO on cell cycle in marmoset iPS cells. Cells of clone B8 were exposed to the indicated concentrations of DMSO
in differentiation medium, as described in Methods, for 24 hours. Following this incubation cells were fixed and stained with
propidium iodide for cell cycle analysis. The percentages of cells under each condition in G1, S and G2 are indicated.
149Marmoset iPS cells: Robust neural differentiation following pretreatment with DMSOof the aims of the procedure in a feasible length of time.
Given that biopsies of tissues from a living animal can be used
to prepare iPS cells via validated reprogramming methods
(Mishra et al., in press), it is then critical to be able to perform
directed differentiation of the cells using protocols that can
be applied to any iPS cell clone that is generated during
reprogramming. Autologous cell therapy would be much more
difficult if optimization of differentiation protocols were
required to be performed for each iPS cell clone. Neverthe-
less, the reported variability in response of pluripotent cells to
directed differentiation (Chang et al., 2008; Osafune et al.,
2008; Hu et al., 2010; Bock et al., 2011) forms an obstacle that
must be addressed.
Here, we confirmed the variability in responsiveness of
pluripotent cells, using marmoset iPS cell clones subjected to a
directed neural differentiation protocol. A clone that was used
to develop the protocol responded well in terms of expected
changes in gene expression, while 2 others responded variably
and less well. However, following pretreatment with DMSO for
24 hours, all clones responded with large changes in gene
expression, and the clone used for the protocol development
also showed increased expression of most genes. The unifor-
mity of the changes in gene expression was confirmed using amicroarray analysis of the 3 clones following DMSO pretreat-
ment and directed differentiation. A further analysis of 6 genes
that were highly upregulated and 6 genes that were highly
downregulated showed that DMSO pretreatment caused a high
degree of uniformity of response in these 12 genes among the 3
iPS cell clones. Using the pretreatment with DMSO as an added
step in an improved protocol, we showed robust expression of
several proteins by immunocytochemistry.
In its effect on enhancing differentiation of a large
variety of human pluripotent stem cells, the effect of DMSO
was thought to be mediated by causing an exit of the
pluripotent cells from the cell cycle and greater effective-
ness of differentiation factors in G1 (Chetty et al., 2013).
However, in our experiments we observed clear effects of
DMSO at very low concentrations, which are unlikely to have
an effect on cell growth rate, and a direct test of higher
concentrations of DMSO showed no effect of this agent on
cell cycle distribution. It is unlikely that in this case DMSO
acts by creating a G1 phase in cells that normally lack it. It is
likely that the effects of DMSO are more complex. DMSO has
long been established as a potent agent for the differenti-
ation of pluripotent and multipotent stem cells of various
kinds (Preisler and Giladi, 1975; Gusella et al., 1976;
150 Z. Qiu et al.McBurney et al., 1982; Santos et al., 2003; Iwatani et al.,
2006) and in these cases it has not been possible to
reproduce its actions using other factors that cause exit
from the cell cycle.
In conclusion, DMSO pretreatment in conjunction with an
established neural differentiation protocol will be valuable,
if not essential, for autologous cell therapy experiments in
the marmoset.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2015.05.010.
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